JP2024542192A5 - - Google Patents
Info
- Publication number
- JP2024542192A5 JP2024542192A5 JP2024529415A JP2024529415A JP2024542192A5 JP 2024542192 A5 JP2024542192 A5 JP 2024542192A5 JP 2024529415 A JP2024529415 A JP 2024529415A JP 2024529415 A JP2024529415 A JP 2024529415A JP 2024542192 A5 JP2024542192 A5 JP 2024542192A5
- Authority
- JP
- Japan
- Prior art keywords
- tigit
- immunoglobulin
- bispecific antibody
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111359665.8A CN116135884A (zh) | 2021-11-17 | 2021-11-17 | 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 |
| CN202111359665.8 | 2021-11-17 | ||
| PCT/CN2022/132422 WO2023088337A1 (zh) | 2021-11-17 | 2022-11-17 | 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542192A JP2024542192A (ja) | 2024-11-13 |
| JP2024542192A5 true JP2024542192A5 (enExample) | 2025-11-25 |
Family
ID=86332938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529415A Pending JP2024542192A (ja) | 2021-11-17 | 2022-11-17 | Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250019436A1 (enExample) |
| EP (1) | EP4435010A4 (enExample) |
| JP (1) | JP2024542192A (enExample) |
| KR (1) | KR20240103034A (enExample) |
| CN (2) | CN116135884A (enExample) |
| AU (1) | AU2022389530A1 (enExample) |
| CA (1) | CA3238571A1 (enExample) |
| WO (1) | WO2023088337A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202511295A (zh) * | 2023-08-31 | 2025-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途 |
| WO2025183487A1 (en) * | 2024-02-29 | 2025-09-04 | Yuhan Corporation | Anti-tigit/anti-pd-l1 bispecific antibody and use thereof |
| CN117924510B (zh) * | 2024-03-21 | 2024-06-04 | 北京星基贝勤生物科技有限公司 | 靶向egfr和axl的双特异性抗体及其药物偶联物与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| PE20181046A1 (es) * | 2015-09-25 | 2018-07-03 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso |
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| CN115947846A (zh) * | 2019-09-12 | 2023-04-11 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1纳米抗体及其衍生物和用途 |
| CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
| JP2024533993A (ja) * | 2021-08-09 | 2024-09-18 | 普米斯生物技術（珠海）有限公司 | 抗ｔｉｇｉｔ抗体およびその使用 |
| CN116925222A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| CN116925233A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
-
2021
- 2021-11-17 CN CN202111359665.8A patent/CN116135884A/zh active Pending
-
2022
- 2022-11-17 CN CN202280075442.5A patent/CN118251419A/zh active Pending
- 2022-11-17 KR KR1020247019886A patent/KR20240103034A/ko active Pending
- 2022-11-17 AU AU2022389530A patent/AU2022389530A1/en active Pending
- 2022-11-17 JP JP2024529415A patent/JP2024542192A/ja active Pending
- 2022-11-17 CA CA3238571A patent/CA3238571A1/en active Pending
- 2022-11-17 US US18/711,482 patent/US20250019436A1/en active Pending
- 2022-11-17 EP EP22894869.1A patent/EP4435010A4/en active Pending
- 2022-11-17 WO PCT/CN2022/132422 patent/WO2023088337A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241417T1 (hr) | Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba | |
| JP2024542192A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| US8865873B2 (en) | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ | |
| JP2025163055A5 (enExample) | ||
| JP2023539501A5 (enExample) | ||
| CN115551889A (zh) | 抗cd73抗体及其用途 | |
| JP2010535713A5 (enExample) | ||
| JP2025038088A5 (enExample) | ||
| JP2024538669A5 (enExample) | ||
| CN117946278A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2025511289A5 (enExample) | ||
| JP2025507817A5 (enExample) | ||
| JP2024509018A5 (enExample) | ||
| JP2024536881A5 (enExample) | ||
| JP2022512672A5 (enExample) | ||
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JP2023542900A5 (enExample) | ||
| JP2025511288A5 (enExample) | ||
| JP2018528759A5 (enExample) | ||
| JP2024532836A5 (enExample) | ||
| JP2024020436A5 (enExample) | ||
| WO2024001669A1 (zh) | 靶向itga2的抗体和包含此抗体的抗体药物缀合物 | |
| JP2025508779A5 (enExample) | ||
| JP2024542944A5 (enExample) |